Abstract. Oral administration of insulin to control blood glucose has become a hot area of diabetes research. The major issue is to produce enough insulin and prevent insulin degradation in the acidic environment of the stomach. We hypothesize that the natural structure of the cell wall and the endoplasmic reticulum in Ganoderma lucidum should help resist the digestion of insulin produced in these cells, making this fungus a feasible production and a new delivery system for oral insulin. A new mini-proinsulin gene was constructed and was transformed into G. lucidum by the Agrobacteriummediated method. Driven by a strong promoter of GPD isolated from Lentinus edodes, expression of mini-proinsulin reached ≤10.4% of total soluble protein, equal to 174 μg/g wet weight, which is sufficient for oral route. Oral route of transgenic G. lucidum significantly reduced blood glucose in streptozocininduced diabetic rats, as compared to rats fed with saline (P<0.0002) or non-transgenic G. lucidum (P<0.0002). Blood glucose was reduced ≤64% in 80% of diabetic rats. Evaluation of pancreatic pathology showed that 54.5% rats in the transgenic group had no pathological changes, as compared to 25% in the saline group and 33.3% in the non-transgenic group. Rats in transgenic group had insulitis score <2, while 30% of rats in the saline group had insulitis score >2. These experimental results indicate that oral route of mini-proinsulinexpressing G. lucidum can be used to control blood glucose in diabetes and to improve pancreatic cell function.
Introduction
Diabetes is a group of serious diseases characterized by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin (1) , which is the only hormone in the body to decrease blood glucose level. Oral insulin has elicited overwhelming interest and investment in recent years because of its advantage of no pain comparing to insulin injection (2) (3) (4) .
Five alternative strategies of oral insulin delivery have emerged, including penetration enhancers (5) , intestinal coating (6) , protease inhibitors (7), colon site-specific delivery (8) , and insulin microspheres (9, 10) . The key issue of all these strategies is to prevent insulin degradation in the acidic environment of the stomach and digestive environment in the small intestine. However, all these strategies have a high cost because of the need of commercial insulin. Herein for the first time, we provide a new cheaper strategy of oral insulin, using transgenic G. lucidum, the traditional Chinese medical mushroom, to produce enough mini-proinsulin with the growing mycelia of fungus.
Three different ways were applied to increase the expression level of mini-proinsulin in G. lucidum. Because of the similarity of codon preference between fungus and plant, mini-proinsulin was synthesized based on plant bias codon (11) . In order to find a strong promoter to drive the mini-proinsulin gene, we used promoter deletion analysis to optimize the GPD (glyceraldehyde-3-phosphate dehydrogenase) promoter derived from Lentinula edodes, another edible fungus (12) . KDEL sequence (13) , which can greatly enhance retention of heterologous proteins in the ER and thus leads to the increased stability and higher level of accumulation of heterologous proteins, was also added to the C-terminal end of mini-proinsulin. In this study, oral route of the transformed mycelia sufficiently reduced blood glucose levels in streptozocin (STZ)-induced diabetic rats, indicating the potential use of mini-proinsulin-expressing G. lucidum as an efficient strategy for oral insulin delivery.
Materials and methods
Construct of the mini-proinsulin gene. Double-stranded DNA was synthesized to construct 180 bp of the mini-proinsulin gene. The B-chain and the A-chain of human insulin was designed and constructed based on plant codon preference, and both chains were connected to an ORF by a 6-AA sequence of GGPSGG, which has the corresponding nucleotide sequence 'GGA GGA CCA TCT GGA GGA'. The initiation code 'ATG' was added before the B-chain, the stop code 'TAA' was added to the end of the A-chain, and the restriction enzyme sites BamHI and EcoRI were added to the beginning and the end of the constructed gene respectively. To direct intracellular retention of mini-proinsulin protein, the KDEL sequence (AAG GAC GAG CTT) was added before the stop code 'TAA', resulting in the modified miniproinsulin gene InsK. Sequencing of the InsK gene was performed to confirm the construction.
Construct of the G. lucidum expression vector p1300-GinsK. The mini-proinsulin gene InsK was inserted into pGEM-11Z. A 1.4-kb fragment of the PLeGPD promoter isolated from HindIII-BamHI digested pL221 was inserted into HindIIIBamHI digested pGEM11Z-InsK, and the resulting plasmid was named pLInsK. A 1.6 kb of GPD-InsK fragment isolated from HindIII-Sac I digested pLInsK was inserted into pL321b digested with the same enzymes, resulting in the plasmid pbInsK. A 3.4 kb HindIII-KpnI fragment of pbInsK was linked to HindIII-KpnI digested p1300-Super-PAnos to obtain the final construct of the expression vector p1300-GInsK.
Agribacterium-mediated transformation of G. lucidum. G. lucidum was cultured in 500 ml of CYM medium (1% maltose, 2% glucose, 0.2% yeast extract, 0.2% tryptone, 0.05% MgSO 4 · 7H 2 O, 0.46% KH 2 PO 4 ) at 28˚C for 4-5 days. Glass balls were used to distribute the mycelia by agitating twice a day. The expression vector p1300-GInsK was transferred into the Agrobacterium strain LBA4404, which was then cultured overnight at 28˚C at 250 r/min. AS was added on the second day with a final concentration of 200 μmol/l, and Agrobacterium was cultured until the OD 660 reached 0.6-0.8. Mycelia of G. lucidum was collected by filtration through four layers of sterile gauze, rinsed 4 or 5 times with sterile water, and suspended in 1 ml of sterile water. Suspended mycelia (100 μl) was mixed with 100 μl of LBA4404 carrying p1300-GInsK, and cultured at 28˚C for 2 days on CYM solid medium containing 1% Agrose. CYM selective medium (10 ml: 20 μg/ml PPT and 500 μg/ml Cb was added to CYM solid medium) was added to the top of the CYM solid medium. The plate was cultured at 28˚C for another 7-10 days until white regenerative colonies appeared.
PCR procedure and Northern blot analysis. SDS protocols were used to extract total DNA from G. lucidum. Briefly, mycelia of G. lucidum was filtered through two layers of gauze, rinsed with distilled water, and dried in filter paper. Mycelia (0.1 g wet) was collected into 1.5-ml eppendorf tube, frozen in liquid nitrogen and grounded in a glass pestle. DNA extraction buffer was composed of 50 mM EDTA, 0.5 M NaCl, 1.5% SDS, 1% (v/v) ß-mercaptoethanol, and 0.1 M Tris-HCl, pH 8.0. The TRIzol method was used to extract total RNA from G. lucidum. To amplify the InsK DNA fragment, the following primers were used: Forward primer: 5'-GTT AAC CAA CAC CTT TGC GGA T-3', Reverse primer: 5'-GAG AGC AGA TAG AGG TGC AGC A-3'; and 30 cycles of PCR amplification were done at 94˚C for 30 sec, 50˚C for 30 sec, and 72˚C for 30 sec. Another pair of primers was used to amplify the GPD-InsK fragment: Forward primer: 5'-ACC AAG AAA GCT CGT GAA GAG G-3', Reverse primer: 5'-CCG CAA ACA AGG TAA AGA GCC-3', and 30 cycles of PCR amplification was done at 94˚C for 50 sec, 50˚C for 50 sec, and 72˚C for 50 sec. Northern blot analysis was conducted based on the digoxigenin-labeled method.
Western blot analysis and ELISA test. To extract total protein, 50 mg of mycelia frozen in liquid nitrogen was ground, 500 μl of extraction buffer (0.1 M PBS, 0.001% NaN 3 , 0.00029% PMSF) was added to the mycelia powder, the extraction was centrifuged at 12,000 rpm for 5 min, and the supernatant was used for Western blotting and ELISA. Insulin standards (Sigma) were the recombinant human insulin expressed in yeast. Rabbit anti-mini-proinsulin serum (1:10000, antigen was made in glutaraldehyde cross-linked mini-proinsulin expressed in the pET system) and goat antirabbit IgG-AP (1:1000, Bioss) were used in Western blotting. Guinea pig anti-human insulin (1:100, China Institute of Atomic Energy, Isotope Institute) and goat anti-guinea pig IgG-HRP (1:2000, Bioss) were used in the ELISA test.
STZ-induced diabetic rats and treatment with transgenic G.
lucidum. SD rats (48 male) weighting ~250 g were used for animal experiments. Diabetes was induced by a single intraperitoneal injection of STZ (60 mg/kg body weight of rat). Seven days after the STZ injection, diabetes onset was evaluated by monitoring blood glucose in rats fasted for 8 h. The rats were considered as diabetic, if the blood glucose level was >14 mmol/l. Mycelia sphere of G. lucidum was processed in a juicer device, and 6 ml of mycelia preparation was injected into the stomach. Thirty diabetic rats were selected and evenly divided into three groups comprising of 10 animals in each group as follows: saline group (fed with 6 ml 0.9% NaCl), non-transgenic group (fed with 6 ml mycelia preparation of non-transgenic G. lucidum), and transgenic group (fed with 6 ml mycelia preparation of transgenic G. lucidum). Blood glucose levels were tested 4 and 20 h after the treatment.
Pancreatic pathology and degree of insulitis. Diabetic rats were fed with 6 ml of saline or mycelia preparation once a week for 4 weeks. One week after the last feeding, the rats from each group were sacrificed for the analysis of pancreatic pathology. Pancreas tissues were removed and fixed in 10% formalin, stained with hematoxylin and eosin (H&E), sectioned at nonoverlapping levels, and imaged with x20 optical microscope. Pancreatic pathology was evaluated as follows: 0, normal islet with no pathological changes; 0.5, suspicious pathological changes; 1, slight changes; 2, medium changes; 3, severe changes. Degree of insulitis was scored as follows: 0, normal islet with no sign of T cell infiltration; 1, islet associated with perivascular, periductal leukocytic infiltration only; 2, more extensive peri-islet infiltration, but with lymphocytes with <50% islet destruction; 3, >50% islet destruction.
Results

Construct of the mini-proinsulin gene.
The B chain and A chain of the insulin gene were designed based on the sequence of the human insulin gene (GenBank GI: 69307). Amino acids in the B chain and A chain were optimized based on plant codon preference. A short chain (GGPSGG) was added to connect the B chain and the A chain. The initiation code ATG was added to the B chain and the termination code TAA was added to the A chain. The KDEL sequence was added to the C-terminal of the A chain. The resulting gene was named mini-proinsulin gene, InsK (Fig. 1A ). The InsK gene was then inserted to the pGEM-11Z vector. Gene sequencing was performed to confirm the sequence of the constructed InsK gene. Gene expression vector p1300-GInsK, as its T-DNA region shown in Fig. 1B , was introduced into G. lucidum using the Agribacterium-mediated method. Secondary structure prediction of mini-proinsulin using TopPred 2 software is shown in Fig. 2 .
Obtaining the mini-proinsulin-expressing G. lucidum. The InsK gene was introduced into G. lucidum using the Agribacteriummediated method. Transgenic G. lucidum regenerated in CYM selective medium containing 20 μg/ml PPT (Fig. 3A) was transferred into new CYM selective medium (Fig. 3B) . Positive transgenic lines of G. lucidum were cultured to obtain the fruit body (Fig. 3C ).
Molecular analysis of transgenic G. lucidum. The SDS method was used to isolate total DNA from transgenic G. lucidum, and both InsK gene (Fig. 4A) and GPD-InsK fragment (Fig. 4B ) (Fig. 4D) .
Short-term effect of transgenic G. lucidum in STZ-induced diabetic rats.
In separate groups, saline solution, non-transgenic G. lucidum, or transgenic G. lucidum were fed to the STZinduced diabetic rats. Four hours after the administration, blood glucose levels had no significant change in the saline or the non-transgenic group, as shown in Fig. 5 . In contrast, blood glucose levels were significantly decreased 4 h after oral route of transgenic G. lucidum in STZ-induced diabetic rats (P<0.0002; Student's test). The result indicates that mini- Table I . Pancreatic pathology in STZ diabetic rats.
-----------------------------------------------------------------------------------------------------Degree of
No. of rats in the No. of rats in the No. of rats in the pathology saline group transgenic group 0  3  6  4  0.5  3  2  2  1  1  -1  2  -1  3  3  5  2 
non-transgenic group -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
0, normal islet with no pathological changes; 0.5, suspicious pathological changes; 1, slight changes; 2, medium changes; 3, severe changes. Table II . Degree of insulitis in STZ diabetic rats.
-----------------------------------------------------------------------------------------------------Degree of
No. of rats in the No. of rats in the No. of rats in the insulitis saline group transgenic group non-transgenic group - 0  2  5  6  1  5  5  6  2  3  --3  ---- 
----------------------------------------------------------------------------------------------------
0, normal islet with no sign of T cell infiltration; 1, islet associated with perivascular, periductal leukocytic infiltration only; 2, more extensive periislet infiltration, but with lymphocytes with <50% islet destruction; 3, >50% islet destruction.
- ------------------------------------------------------------------------------------------------ ---- proinsulin expressed in the transgenic G. lucidum take its biological effect of down-regulation of the blood glucose level in vivo.
Long-term effect of transgenic G. lucidum in STZ-induced diabetic rats. As shown in Fig. 6A , blood glucose levels were compared between rats #35 and #124. In rat #35, which received saline, blood glucose levels remained unchanged from the baseline up to 20 h. In rat #124, which received transgenic G. lucidum, blood glucose level decreased by 64% below baseline in 4 h, subsequently returning to baseline in 20 h. As shown in Fig. 6B , significant reduction of blood glucose levels were observed in 80% of diabetic rats in the transgenic group, with the highest reduction of 64%.
Attenuation of pancreatic pathology by oral route of transgenic G. lucidum. The long-term effect of transgenic G. lucidum on pancreatic pathology was evaluated after 4 weeks of weekly oral route administration. Absence of pathological changes were observed in 54.5% of diabetic rats in the transgenic group, compared to 33.3% in the non-transgenic and 25% in the saline groups. Corresponding rates of severe pathological changes were 18.2, 16.7 and 41.7% (Table I) . Pathological changes were evaluated through photomicrograph of pancreatic tissue (original magnification, x25; H&E stain). Large areas of hemorrhage were found in pancreatic tissue of the saline group; moreover, the acinar structure was obscure and there were large areas of necrosis, nuclear lysis, and the presence of saponified spots (Fig. 7A and B) . In contrast, intact healthy islets with normal secretory cells rich in cytoplasm were observed in both transgenic and nontransgenic groups (Fig. 7C-F) . Since non-transgenic G. lucidum also ameliorated pancreatic pathology, we speculate that G. lucidum, a traditional Chinese medicine, may play a curative role by improving the immune system. This is also the reason we chose G. lucidum as the transgenic target. We expected that oral route of G. lucidum transformed with the mini-proinsulin gene would not only reduce blood glucose in the short-term but also relieve pancreatic pathology in the long-term.
Inhibition of insulitis by oral route of transgenic G. lucidum.
To determine the degree of pathology, we graded insulitis on an ascending scale of 0-5. Only 20% of rats in the saline group had a grade of 0 (Fig. 8A) ; in contrast, 50% of the rats in both the transgenic and non-transgenic group had grade of 0 (Table II) . In addition, 50% of the rats in all three groups had a grade of 1 (Fig. 8B) ; 30% of the rats in the saline group had a grade of 2 ( Fig. 8C) , which was not observed in either the transgenic or non-transgenic group (Table II) . These results suggest that both transgenic and non-transgenic G. lucidum can inhibit insulitis to some extent.
Discussion
Although it was demonstrated by Arakawa et al that oral administration of transgenic potato tubes expressing CTBinsulin can reduce the occurrence of diabetes in type I diabetes in NOD mice (14, 15) , there are two major advances in our study. Firstly, the expression level of mini-proinsulin reached ≤10.4% of total soluble protein, equal to 174 μg/g wet weight, which is far more than the level ≤0.05% of total soluble protein in potato tubes (14) . Secondly, oral route of transgenic G. lucidum decreased the blood glucose level in 4 h and attenuated pancreatic pathology and inhibited insulitis in 4 weeks, while oral route of transgenic potato tubes inhibited insulitis in 30 weeks (14) .
Higher fungus such as G. lucidum is a good bioreactor to produce therapeutic proteins; it is well known only for its natural forms in potential medical function (16) (17) (18) . In addition to its original medical usage and advantage of no side effects, transgenic G. lucidum is also a new strategy of oral insulin. Our experimental design was to use G. lucidum to deliver both the exogenous mini-proinsulin and other natural medicinal contents of this fungus to treat diabetes. As a long-used medicinal fungus, G. lucidum has shown various effects in enhancing the immune system, inhibiting tumors, and improving diabetes (16) (17) (18) .
High expression of mini-proinsulin in G. lucidum is a critical prerequisite for its direct effects on down-regulation of blood glucose and oral immune tolerance. The Agrobacterium-mediated method in the transformation of G. lucidum was not been reported previously, although G. lucidum has been successfully transformed by other methods, such as electroporation and restriction enzyme-mediated integration (12, 19) . For the first time, a new method of Agrobacterium-mediated gene transformation was developed based on the method applied in Trichoderma Harzianum. While spores were used as the transgenic target in T.
Harzianum, the filamentous fungus was used to transform G. lucidum (20) .
The human mini-proinsulin is characterized by a C-chain peptide consisting of only 9 amino acids (21) (22) (23) (24) , whereas the C-chain peptide of natural human proinsulin is made up of 35 amino acids. The bridge between B chain and A chain is only 16.12 Å, and 16 Å is the minimum distance between a five-AA protein; hence, a three to five amino acid should be able to connect the C terminal B chain and the N terminal A chain, forming a modified protein which has the same function as natural insulin. The advantage of using the mini-proinsulin gene is that the A-chain and the B-chain of the insulin gene can be expressed in one ORF, and that the short substituting C-peptide made the structure of mini-proinsulin more like insulin. We need to point out that ß-turn structure was taken into serious consideration in the design of our linking peptide. Different amino acids have various preferences and capabilities in forming the second structure. While Pro and Gly barely form α-helix and ß-sheet, ß-turns are common structures in Pro, Gly, Asn and Ser (25, 26) , suggesting that ß-turns can be easily formed in Gly-Pro-Ser. Therefore, we chose Gly-Gly-Pro-Ser-Gly-Gly as the linking peptide.
Under the new concept of insulin coating, mini-proinsulin was not only produced within the cells, but also protected by the natural structure of the cell wall, plasma membrane, and endoplasmic rectum. Therefore, expressing mini-proinsulin in the bioreactor G. lucidum provides a novel strategy in oral administration of insulin. In contrast to the CTB-INS fusion protein expressed in transgenic potato plants (14) , transgenic G. lucidum significantly reduced blood glucose in diabetic rats within 4 h of oral administration, and it attenuated the pancreatic tissue pathological changes and insulitis in STZinduced diabetic rats after 4 weeks of oral administration. These experimental results provide a new direction for the treatment of diabetes.
